Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CR6086

Phase 2Small molecule

RRottapharm Biotech

CR6086 is one of 25 small molecule programs targeting Metastatic. It is currently in Phase 2.

1

Indications

2

Total Trials

1

Active Trials

24

Competitors

Pipeline

Status by Indication[3][1]

Indication

MetastaticActive, not recruiting

MetastaticPhase 2

Active, not recruiting

Competition

Competitive Landscape

27 competitors in Metastatic

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Keytruda

Tecentriq

Padcev

Trodelvy

Erbitux

Jemperli

GGlaxo Dba Glaxosmithkline

Imbruvica

PPharmacyclics LLC.

Zejula

GGlaxo Dba Glaxosmithkline

JMKX001899

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Active, not recruiting

Metastatic

NCT05205330

Clinical

Trials by Indication[1]

Rheumatoid Arthritis1 trial

A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis

Completed·RRottapharm Biotech·Phase 2·NCT03163966·248 enrolled

Metastatic1 trial

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

Active, not recruiting·RRottapharm Biotech·Phase 1/2·NCT05205330·107 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CR6086. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CR6086 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CR6086. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rottapharm Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRottapharm Biotech

Related News